SE0300988D0 - New use - Google Patents

New use

Info

Publication number
SE0300988D0
SE0300988D0 SE0300988A SE0300988A SE0300988D0 SE 0300988 D0 SE0300988 D0 SE 0300988D0 SE 0300988 A SE0300988 A SE 0300988A SE 0300988 A SE0300988 A SE 0300988A SE 0300988 D0 SE0300988 D0 SE 0300988D0
Authority
SE
Sweden
Prior art keywords
new use
angiotensin
prevention
treatment
combination
Prior art date
Application number
SE0300988A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Ljunggren
Anders Svensson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0300988A priority Critical patent/SE0300988D0/xx
Publication of SE0300988D0 publication Critical patent/SE0300988D0/xx
Priority to KR1020057017718A priority patent/KR20050114671A/ko
Priority to BRPI0408979-0A priority patent/BRPI0408979A/pt
Priority to CA002520960A priority patent/CA2520960A1/en
Priority to JP2006507997A priority patent/JP2006522115A/ja
Priority to US10/550,760 priority patent/US20060194856A1/en
Priority to EP04724927A priority patent/EP1613309A1/en
Priority to AU2004226517A priority patent/AU2004226517B2/en
Priority to MXPA05010660A priority patent/MXPA05010660A/es
Priority to CNA2004800093941A priority patent/CN1771033A/zh
Priority to PCT/SE2004/000505 priority patent/WO2004087136A1/en
Priority to NZ542640A priority patent/NZ542640A/en
Priority to IL170706A priority patent/IL170706A0/en
Priority to NO20054370A priority patent/NO20054370L/no
Priority to ZA200507945A priority patent/ZA200507945B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0300988A 2003-04-03 2003-04-03 New use SE0300988D0 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use
NZ542640A NZ542640A (en) 2003-04-03 2004-03-31 Use of angiontensin II antagonists including losartan, candesartan, cilexetil, irbesartan and candesartan for the treatment or prevention of metabolic syndrome or Syndrome X
EP04724927A EP1613309A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome
MXPA05010660A MXPA05010660A (es) 2003-04-03 2004-03-31 Uso de anti-antagonistas para el tratamiento o prevencion de sindrome metabolico.
CA002520960A CA2520960A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome
JP2006507997A JP2006522115A (ja) 2003-04-03 2004-03-31 代謝症候群の処置または予防のためａｔｉｉアンタゴニストの使用
US10/550,760 US20060194856A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome
KR1020057017718A KR20050114671A (ko) 2003-04-03 2004-03-31 대사 증후군의 치료 또는 예방을 위한 ａｔｉｉ 길항제의용도
AU2004226517A AU2004226517B2 (en) 2003-04-03 2004-03-31 Use of ATII antagonist for the treatment or prevention of metabolic syndrome
BRPI0408979-0A BRPI0408979A (pt) 2003-04-03 2004-03-31 uso de um antagonista e receptor de tipo 1 da angiotensina ii sozinho ou em combinação com uma substáncia anti-hipertensiva metabolicamente neutra, e, método para o tratamento e/ou prevenção de sìndrome metabólica
CNA2004800093941A CN1771033A (zh) 2003-04-03 2004-03-31 应用atii拮抗剂治疗或预防代谢综合征
PCT/SE2004/000505 WO2004087136A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome
IL170706A IL170706A0 (en) 2003-04-03 2005-09-06 Use of atii antagonist for the treatment or prevention of metabolic syndrome
NO20054370A NO20054370L (no) 2003-04-03 2005-09-21 Anvendelse av ATII-antagonist for behandling og forhindring av metabolsk syndrom
ZA200507945A ZA200507945B (en) 2003-04-03 2005-09-30 Use of ATII antagonist for the treatment or prevention of metabolic syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use

Publications (1)

Publication Number Publication Date
SE0300988D0 true SE0300988D0 (sv) 2003-04-03

Family

ID=20290927

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use

Country Status (15)

Country Link
US (1) US20060194856A1 (https=)
EP (1) EP1613309A1 (https=)
JP (1) JP2006522115A (https=)
KR (1) KR20050114671A (https=)
CN (1) CN1771033A (https=)
AU (1) AU2004226517B2 (https=)
BR (1) BRPI0408979A (https=)
CA (1) CA2520960A1 (https=)
IL (1) IL170706A0 (https=)
MX (1) MXPA05010660A (https=)
NO (1) NO20054370L (https=)
NZ (1) NZ542640A (https=)
SE (1) SE0300988D0 (https=)
WO (1) WO2004087136A1 (https=)
ZA (1) ZA200507945B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067378A2 (en) * 2006-11-28 2008-06-05 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted phenyltetrazoles
JP2015509969A (ja) * 2012-03-16 2015-04-02 グルソックス・バイオテック・アーベー Ｎｏｘ４阻害活性を示すチオフェン−ベースの化合物および療法におけるその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
GB9406573D0 (en) * 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
DE4439947A1 (de) * 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
NZ509260A (en) * 1998-07-10 2003-09-26 Novartis Ag Pharmaceutical composition containing valsartan and a calcium channel blocker
IL152081A0 (en) * 2000-04-12 2003-05-29 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
EP1579872B8 (en) * 2002-12-27 2012-11-07 Takeda Pharmaceutical Company Limited Body weight gain inhibitor

Also Published As

Publication number Publication date
US20060194856A1 (en) 2006-08-31
MXPA05010660A (es) 2005-12-12
IL170706A0 (en) 2009-02-11
NZ542640A (en) 2008-06-30
AU2004226517A1 (en) 2004-10-14
NO20054370D0 (no) 2005-09-21
AU2004226517B2 (en) 2008-01-24
ZA200507945B (en) 2007-04-25
WO2004087136A1 (en) 2004-10-14
CN1771033A (zh) 2006-05-10
KR20050114671A (ko) 2005-12-06
BRPI0408979A (pt) 2006-04-04
CA2520960A1 (en) 2004-10-14
JP2006522115A (ja) 2006-09-28
EP1613309A1 (en) 2006-01-11
NO20054370L (no) 2005-10-31

Similar Documents

Publication Publication Date Title
DE50306232D1 (de) Ampholytisches copolymer und dessen verwendung
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
EP1467730A4 (en) Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof
SG146657A1 (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
MA28512B1 (fr) Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
JO2356B1 (en) N-by-phenyl derivatives (methyl substituted) amino cycloalkan carboxamide
ZA200500966B (en) Biphasic composition induced by polydextrose and sucrose
ATE371645T1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
DE60221234D1 (de) Verwendung von füllstoffe als sättigungsmittel
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
EA200100937A1 (ru) Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов
UY28941A1 (es) Indazoles sustituidos, composiciones que los contienen, procedimiento de preparacion y su uso
UA85574C2 (uk) Ендопаразитоцидний засіб для місцевого застосування
WO2006137934A3 (en) Purposeful movement of human migratory cells away from an agent source
EA200100936A1 (ru) Способы и композиции, использующие (+)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
SG149872A1 (en) Antagonists of the bradykinin b1 receptor
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
DE602005012806D1 (en) Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten
MY137620A (en) Therapeutic treatment
SE0301650D0 (sv) Novel compounds